Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00143
|
|||||
| Drug Name |
Vincristine
|
|||||
| Synonyms |
22-Oxovincaleukoblastine; Indole alkaloid; LCR; Leurocristine; Lilly37231 (1:1 sulfate salt); Liposomal Vincristine; Marqibo; Onco TCS; Oncovin (1:1 sulfate salt); Oncovin (TN); Oncovine; Tecnocris; Tecnocris (TN); VCR; VIN; Vincaleukoblastine, 22-oxo-22-Oxovincaleukoblastine; Vincasar; Vincasar (1:1 sulfate salt); Vincrex (1:1 sulfate salt); Vincristina; Vincristina [DCIT]; Vincristine (INN); Vincristine [INN:BAN]; Vincristinum; Vincristinum [INN-Latin]; Vincrstine; Vincrystine; Vinkristin; Z-D-Val-Lys(Z)-OH
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Acute lymphoblastic leukemia [ICD11:2B33.0] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C46H56N4O10
|
|||||
| Canonical SMILES |
CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
|
|||||
| InChI |
InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1
|
|||||
| InChIKey |
OGWKCGZFUXNPDA-XQKSVPLYSA-N
|
|||||
| CAS Number |
CAS 57-22-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 825 | Topological Polar Surface Area | 171 | ||
| Heavy Atom Count | 60 | Rotatable Bond Count | 10 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 12 | |||
| XLogP |
2.8
|
|||||
| PubChem CID | ||||||
| PubChem SID |
104029594
,104310773
,11431056
,124892473
,124892475
,126687244
,127301091
,127301092
,127301093
,127301094
,127301095
,127301096
,127301097
,127301098
,127301099
,127301100
,127301101
,127301102
,127301103
,127301104
,127301105
,127301106
,127301107
,127301108
,127301109
,127301110
,127301111
,127301112
,127301113
,127301114
,127301115
,127301116
,127301117
,14717665
,14889382
,26757081
,29224994
,46507033
,48424284
,49854447
,53788615
,56312035
,56314177
,57323093
,598397
,74979043
,8153716
,92309095
,9413
,96025362
|
|||||
| ChEBI ID |
ChEBI:28445
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP1 | Transporter Info | Multidrug resistance-associated protein 1 | Substrate | [3] | ||
| MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [4] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [5] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | P-GP | Transporter Info | Km =3.7 microM | Spodoptera frugiperda (Sf9) cells-MDR1 | [6] | |
| References | ||||||
| 1 | Vincristine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34. | |||||
| 3 | Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol. 2008 Sep 4;591(1-3):128-31. | |||||
| 4 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | |||||
| 5 | L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett. 2010 Feb 15;192(3):408-18. | |||||
| 6 | Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.